In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Go van Dam, CEO & Founder at TRACER.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Go, covering:

• The value of micro-dosing and fluorescent imaging in small patient populations at the preclinical proof of concept phase, and the benefits to investors, biotech and big pharma.

Prof. Go van Dam is the CEO and Co-Founder of TRACER, a Clinical Research Organisation specialising in generating fast and accurate in-human data with nuclear and optical molecular imaging techniques, even before the classical Phase I-III studies. Go is seen as a pioneer in the optical imaging field with groundbreaking research to his name. 

Go originated as a surgeon oncologist and professor of Surgery at Groningen University. He trained at Harvard, the Mayo Clinic and NCI. Go executed and published the 1st in-human application of targeted fluorescence imaging in 2011 (Nature Medicine) and published more than 140 papers predominantly about clinical translation of innovative targeted optical molecular imaging. He currently focuses on utilising his validated optical imaging expertise in the life sciences industry to reduce R&D innovation costs, shorten time-to-market, and increased efficiency for innovative drug development.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

We are also proudly supported by Zymewire, which is the leader in actionable sales intelligence for life science Business development professionals. In fact, thousands of life science BD professionals start their day with sales signals from Zymewire. Learn more at tryzymewire.com